The number of diabetes patients in China is increasing continually. To curb the high incurrence of diabetes, the intervention in the pre-diabetes phase is of great importance. In this regard, Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy Sciences (CAS) and Novo Nordisk have decided to collaborate in certain respects in the area of pre-diabetes research and development, and establish a joint research centre for pre-diabetes named "SIBS-Novo Nordisk Translational Research Centre for Pre-Diabetes". The "Translational Research Centre for Pre-Diabetes" is the first of its kind in China, and it is also an entrance to prevention medicine for Chinese diabetes treatments.